[go: up one dir, main page]

DK3625263T3 - Anti-galectin- 9-antistoffer og anvendelser deraf - Google Patents

Anti-galectin- 9-antistoffer og anvendelser deraf

Info

Publication number
DK3625263T3
DK3625263T3 DK18870270.8T DK18870270T DK3625263T3 DK 3625263 T3 DK3625263 T3 DK 3625263T3 DK 18870270 T DK18870270 T DK 18870270T DK 3625263 T3 DK3625263 T3 DK 3625263T3
Authority
DK
Denmark
Prior art keywords
galectin
antibodies
Prior art date
Application number
DK18870270.8T
Other languages
English (en)
Inventor
Shohei Koide
George Miller
Akiko Koide
Aleksandra Filipovic
Eric Elenko
Joseph Bolen
Linxiao Chen
Original Assignee
Univ New York
Puretech Lyt Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=66246040&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3625263(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ New York, Puretech Lyt Inc filed Critical Univ New York
Application granted granted Critical
Publication of DK3625263T3 publication Critical patent/DK3625263T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
DK18870270.8T 2017-10-27 2018-10-29 Anti-galectin- 9-antistoffer og anvendelser deraf DK3625263T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762578111P 2017-10-27 2017-10-27
US201862665175P 2018-05-01 2018-05-01
US201862736317P 2018-09-25 2018-09-25
PCT/US2018/058028 WO2019084553A1 (en) 2017-10-27 2018-10-29 ANTI-GALECTIN-9 ANTIBODIES AND USES THEREOF

Publications (1)

Publication Number Publication Date
DK3625263T3 true DK3625263T3 (da) 2025-06-30

Family

ID=66246040

Family Applications (1)

Application Number Title Priority Date Filing Date
DK18870270.8T DK3625263T3 (da) 2017-10-27 2018-10-29 Anti-galectin- 9-antistoffer og anvendelser deraf

Country Status (14)

Country Link
US (5) US10344091B2 (da)
EP (2) EP4597112A2 (da)
JP (5) JP6873445B2 (da)
KR (1) KR102162129B1 (da)
CN (2) CN115261392B (da)
AU (3) AU2018355588C1 (da)
CA (1) CA3080120C (da)
DK (1) DK3625263T3 (da)
ES (1) ES3032734T3 (da)
IL (3) IL280648B2 (da)
PT (1) PT3625263T (da)
SG (1) SG11202003652QA (da)
WO (1) WO2019084553A1 (da)
ZA (3) ZA202002246B (da)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES3032734T3 (en) 2017-10-27 2025-07-24 Univ New York Anti-galectin-9 antibodies and uses thereof
CN111256416B (zh) * 2018-11-30 2025-09-09 海尔智家股份有限公司 风冷冰箱
US20220204629A1 (en) * 2019-03-25 2022-06-30 New York University Anti-galectin-9 antibodies and uses thereof
WO2020223702A1 (en) * 2019-05-01 2020-11-05 New York University Anti-galectin-9 antibodies and uses thereof
KR20220016152A (ko) * 2019-05-31 2022-02-08 더 카운실 오브 더 퀸즐랜드 인스티튜트 오브 메디컬 리서치 항-gal9 결합분자 활성화
WO2020237320A1 (en) * 2019-05-31 2020-12-03 The Council Of The Queensland Institute Of Medical Research Anti-gal9 immune-inhibiting binding molecules
KR20220012932A (ko) * 2019-06-24 2022-02-04 유피엠-큄메네 코퍼레이션 나노피브릴 셀룰로스 하이드로겔 내에 진핵생물 세포를 포함하는 이식가능한 세포 조성물, 그 제조 방법 및 나노피브릴 셀룰로스의 용도
US20220242955A1 (en) * 2019-07-11 2022-08-04 Dana-Farber Cancer Institute, Inc. Targeting galectin-9 as a therapeutic strategy for t-cell exhaustion in t-cell acute lymphoblastic leukemia
WO2021022256A1 (en) * 2019-08-01 2021-02-04 New York University Combined cancer therapy of anti-galectin-9 antibodies and chemotherapeutics
CA3147827A1 (en) * 2019-08-14 2021-02-18 Modmab Therapeutics Inc. Antibodies that bind to lrp5 proteins and methods of use
WO2021139682A1 (en) * 2020-01-07 2021-07-15 Hifibio (Hk) Limited Anti-galectin-9 antibody and uses thereof
US20230295564A1 (en) * 2020-07-23 2023-09-21 Emory University Galectin-9 Specific Binding Agents for Use in Treating Cancer
WO2022031710A2 (en) * 2020-08-04 2022-02-10 Exelixis, Inc. Multispecific binding agents and uses thereof
EP4192501A1 (en) * 2020-08-04 2023-06-14 Exelixis, Inc. Cd47 binding agents and uses thereof
CA3187850A1 (en) * 2020-08-04 2022-02-10 Bryan Glaser Pd-l1 binding agents and uses thereof
WO2022093841A1 (en) * 2020-10-26 2022-05-05 Puretech Lyt, Inc. Anti-galectin-9 antibodies and uses thereof in the treatment of ocular melanoma
WO2022109302A1 (en) * 2020-11-20 2022-05-27 New York University Anti-galectin-9 antibodies and therapeutic uses thereof
CA3209741A1 (en) * 2021-02-26 2022-09-01 Shohei Koide Compositions and methods comprising antibodies that bind to covalent peptide conjugates
WO2022232653A1 (en) * 2021-04-30 2022-11-03 Puretech Lyt, Inc. Combination of anti-galectin-9 antibodies and chemotherapeutics for use in cancer therapy
US20240279331A1 (en) * 2021-06-11 2024-08-22 The Regents Of The University Of California Antibodies that stimulate nk cell-mediated cytotoxicity
WO2023060192A2 (en) * 2021-10-06 2023-04-13 The University Of Chicago Survivin targeting polypeptides for detection and treatment of cancer
JPWO2023112454A1 (da) * 2021-12-16 2023-06-22
WO2023245021A2 (en) * 2022-06-14 2023-12-21 Invenra Inc. Multispecific binding agents that target cd25 and/or ctla4 and uses thereof
CA3260580A1 (en) * 2022-06-29 2024-01-04 Puretech Lyt Inc TREATMENT OF HEMATOLOGICAL MALIGNANCIES WITH GALECTIN-9 INHIBITING ANTIBODIES
US20240277122A1 (en) * 2023-02-16 2024-08-22 Dongguan Casekey Industry Co., Ltd Card fixation assembly for card holder and card holder
WO2024258870A2 (en) 2023-06-12 2024-12-19 Amgen Inc. Lymphotoxin beta receptor agonist binding proteins
WO2025014933A1 (en) * 2023-07-10 2025-01-16 Northwestern University Targeting tim-3 in mapk-driven glioma
WO2025085792A1 (en) * 2023-10-19 2025-04-24 Puretech Lyt, Inc. Treatment of hematological malignancies with antibodies inhibiting galectin-9
WO2025129249A1 (en) * 2023-12-22 2025-06-26 Commonwealth Scientific And Industrial Research Organisation Identifying sequence functionality

Family Cites Families (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4777127A (en) 1985-09-30 1988-10-11 Labsystems Oy Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4868103A (en) 1986-02-19 1989-09-19 Enzo Biochem, Inc. Analyte detection by means of energy transfer
US4704692A (en) 1986-09-02 1987-11-03 Ladner Robert C Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
GB8702816D0 (en) 1987-02-07 1987-03-11 Al Sumidaie A M K Obtaining retrovirus-containing fraction
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
US5422120A (en) 1988-05-30 1995-06-06 Depotech Corporation Heterovesicular liposomes
AP129A (en) 1988-06-03 1991-04-17 Smithkline Biologicals S A Expression of retrovirus gag protein eukaryotic cells
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
EP1997891A1 (en) 1988-09-02 2008-12-03 Dyax Corporation Generation and selection of recombinant varied binding proteins
EP0454781B1 (en) 1989-01-23 1998-12-16 Chiron Corporation Recombinant cells for therapies of infection and hyperproliferative disorders and preparation thereof
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
DE69034168T3 (de) 1989-03-21 2013-04-11 Vical, Inc. Expression von exogenen Polynukleotidsequenzen in Wirbeltieren
EP1645635A3 (en) 1989-08-18 2010-07-07 Oxford Biomedica (UK) Limited Replication defective recombinant retroviruses expressing a palliative
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
NZ237464A (en) 1990-03-21 1995-02-24 Depotech Corp Liposomes with at least two separate chambers encapsulating two separate biologically active substances
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
AU665190B2 (en) 1990-07-10 1995-12-21 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
WO1992009690A2 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with altered binding properties
ATE439435T1 (de) 1991-03-01 2009-08-15 Dyax Corp Chimäres protein mit mikroprotein mit zwei oder mehr disulfidbindungen und ausgestaltungen davon
DE69233750D1 (de) 1991-04-10 2009-01-02 Scripps Research Inst Bibliotheken heterodimerer Rezeptoren mittels Phagemiden
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
DE69233013T2 (de) 1991-08-20 2004-03-04 The Government Of The United States Of America As Represented By The Secretary Of National Institute Of Health, Office Of Technology Transfer Adenovirus vermittelter gentransfer in den gastrointestinaltrakt
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
WO1993010218A1 (en) 1991-11-14 1993-05-27 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Vectors including foreign genes and negative selective markers
GB9125623D0 (en) 1991-12-02 1992-01-29 Dynal As Cell modification
CA2087413A1 (en) 1992-01-17 1993-07-18 Joseph R. Lakowicz Fluorescent energy transfer immunoassay
FR2688514A1 (fr) 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
JPH07507689A (ja) 1992-06-08 1995-08-31 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 特定組織のターゲティング方法及び組成物
JPH09507741A (ja) 1992-06-10 1997-08-12 アメリカ合衆国 ヒト血清による不活性化に耐性のあるベクター粒子
SE9201984D0 (sv) 1992-06-29 1992-06-29 Pharmacia Biosensor Ab Improvement in optical assays
GB2269175A (en) 1992-07-31 1994-02-02 Imperial College Retroviral vectors
CA2592997A1 (en) 1992-12-03 1994-06-09 Genzyme Corporation Pseudo-adenovirus vectors
US5981568A (en) 1993-01-28 1999-11-09 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
AU6818094A (en) 1993-04-22 1994-11-08 Depotech Corporation Cyclodextrin liposomes encapsulating pharmacologic compounds and methods for their use
JP3532566B2 (ja) 1993-06-24 2004-05-31 エル． グラハム，フランク 遺伝子治療のためのアデノウイルスベクター
EP0694070B1 (en) 1993-09-15 2002-04-10 Chiron Corporation Recombinant alphavirus vectors
US6015686A (en) 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
JP3875990B2 (ja) 1993-10-25 2007-01-31 カンジ，インコーポレイテッド 組換えアデノウイルスベクターおよび使用方法
NZ276305A (en) 1993-11-16 1997-10-24 Depotech Corp Controlled release vesicle compositions
WO1995030763A2 (en) 1994-05-09 1995-11-16 Chiron Viagene, Inc. Retroviral vectors having a reduced recombination rate
WO1996017072A2 (en) 1994-11-30 1996-06-06 Chiron Viagene, Inc. Recombinant alphavirus vectors
US6265150B1 (en) 1995-06-07 2001-07-24 Becton Dickinson & Company Phage antibodies
AU2998597A (en) 1996-05-06 1997-11-26 Chiron Corporation Crossless retroviral vectors
PT971946E (pt) 1997-01-21 2006-11-30 Gen Hospital Corp Selecção de proteínas utilizando fusões arn-proteína
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
AU3734900A (en) 1999-03-09 2000-09-28 University Of Southern California Method of promoting myocyte proliferation and myocardial tissue repair
KR20030061384A (ko) 2000-11-01 2003-07-18 가르파마 컴퍼니 리미티드 암 전이능 검출제
ES2405551T3 (es) 2001-10-01 2013-05-31 Dyax Corporation Vectores de presentación eucariotas multicatenarios y usos de los mismos
JP2004244411A (ja) * 2003-01-24 2004-09-02 Galpharma Co Ltd ガレクチン９含有医薬
KR20050103474A (ko) * 2003-01-24 2005-10-31 가르파마 컴퍼니 리미티드 갈렉틴 9 함유 의약
EP2591786B1 (en) 2003-10-16 2017-04-12 Cancure Limited Immunomodulating compositions and uses therefor
KR20070107687A (ko) 2004-12-31 2007-11-07 제넨테크, 인크. Ｂｒ３과 결합하는 폴리펩티드, 및 그의 용도
US20070237764A1 (en) 2005-12-02 2007-10-11 Genentech, Inc. Binding polypeptides with restricted diversity sequences
WO2015164330A1 (en) 2014-04-21 2015-10-29 Millennium Pharmaceuticals, Inc. Anti-psyk antibody molecules and use of same for syk-targeted therapy
JP5523345B2 (ja) 2008-01-18 2014-06-18 ジェネンテック， インコーポレイテッド Ｋ６３結合型ポリユビキチンを標的とする方法と組成物
ES2337224B1 (es) 2008-06-11 2011-02-17 Consejo Superior De Investigaciones Cientificas (Csic) (40%) Anticuerpo anti-dectin-1 humano, hibridoma productor de dicho anticuerpo y sus aplicaciones.
MX2011000655A (es) 2008-07-18 2011-03-21 Oragenics Inc Composiciones para la deteccion y tratamiento de cancer colorrectal.
US9163087B2 (en) 2010-06-18 2015-10-20 The Brigham And Women's Hospital, Inc. Bi-specific antibodies against TIM-3 and PD-1 for immunotherapy in chronic immune conditions
AR083819A1 (es) 2010-11-10 2013-03-27 Genentech Inc UN ANTICUERPO QUE SE UNE A BACE1 (ENZIMA 1 DE DISOCIACION DE PROTEINA PRECURSORA DEL AMILOIDE DE SITIO b), METODOS Y COMPOSICIONES PARA INMUNOTERAPIA PARA ENFERMEDAD NEURAL
EP2650361A4 (en) 2010-12-09 2015-09-30 Galpharma Co Ltd GALECTIN-9 DETERGENT CELL, MANUFACTURING METHOD AND APPLICATION THEREOF
WO2012177788A1 (en) 2011-06-20 2012-12-27 La Jolla Institute For Allergy And Immunology Modulators of 4-1bb and immune responses
US20140242095A1 (en) * 2011-10-19 2014-08-28 University Health Network Antibodies and antibody fragments targeting sirp-alpha and their use in treating hematologic cancers
WO2013116590A1 (en) 2012-02-01 2013-08-08 George Miller Inhibition of pattern recognition receptors in pancreatic cancer treatment using tlr inhibitors
WO2015035112A1 (en) 2013-09-05 2015-03-12 The Johns Hopkins University Cancer therapy via a combination of epigenetic modulation and immune modulation
FR3021970B1 (fr) * 2014-06-06 2018-01-26 Universite Sciences Technologies Lille Anticorps dirige contre la galectine 9 et inhibiteur de l'activite suppressive des lymphocytes t regulateurs
SG11201700281SA (en) 2014-07-14 2017-02-27 Queensland Inst Med Res Galectin immunotherapy
EP4368205A1 (en) 2014-09-16 2024-05-15 Innate Pharma Neutralization of inhibitory pathways in lymphocytes
WO2016061504A2 (en) * 2014-10-17 2016-04-21 The University Of Chicago Recombinant antibodies that recongnize the c-terminal domains of ebola virus nucleoprotein
WO2016073299A1 (en) 2014-11-04 2016-05-12 Dana-Farber Cancer Institute, Inc. Anti-galectin antibody biomarkers predictive of anti-immune checkpoint and anti-angiogenesis responses
US20160209425A1 (en) 2015-01-16 2016-07-21 New York University Use of dectin-1 activators for treatment of liver disorders
US10294294B2 (en) 2015-09-10 2019-05-21 Albert Einstein College Of Medicine Synthetic antibodies to BAX and uses thereof
WO2017202962A1 (en) 2016-05-24 2017-11-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of non small cell lung cancer (nsclc) that coexists with chronic obstructive pulmonary disease (copd)
WO2018023113A1 (en) 2016-07-29 2018-02-01 New York University Treating solid tumor by targeting dectin-1 signaling
US20190248920A1 (en) 2016-09-23 2019-08-15 Csl Limited Coagulation factor binding proteins and uses thereof
ES3032734T3 (en) * 2017-10-27 2025-07-24 Univ New York Anti-galectin-9 antibodies and uses thereof
WO2020014465A1 (en) 2018-07-11 2020-01-16 Arrys Therapeutics, Inc. Polymorphic compounds and uses thereof
US20220204629A1 (en) 2019-03-25 2022-06-30 New York University Anti-galectin-9 antibodies and uses thereof
WO2020223702A1 (en) 2019-05-01 2020-11-05 New York University Anti-galectin-9 antibodies and uses thereof

Also Published As

Publication number Publication date
ZA202102905B (en) 2023-04-26
US20190127472A1 (en) 2019-05-02
US11414492B2 (en) 2022-08-16
ZA202002246B (en) 2025-04-30
IL280648B2 (en) 2024-10-01
ZA202303412B (en) 2024-09-25
EP3625263B1 (en) 2025-04-09
CA3080120A1 (en) 2019-05-02
JP2023116789A (ja) 2023-08-22
KR102162129B9 (ko) 2023-02-08
EP4597112A2 (en) 2025-08-06
US20220340666A1 (en) 2022-10-27
IL312910A (en) 2024-07-01
CA3080120C (en) 2023-11-21
PT3625263T (pt) 2025-06-20
JP2021501120A (ja) 2021-01-14
NZ764590A (en) 2020-12-18
JP7092317B2 (ja) 2022-06-28
ES3032734T3 (en) 2025-07-24
US11629191B2 (en) 2023-04-18
JP6873445B2 (ja) 2021-05-19
EP3625263B8 (en) 2025-05-28
IL274152A (en) 2020-06-30
US20190256604A1 (en) 2019-08-22
EP3625263A1 (en) 2020-03-25
AU2018355588B2 (en) 2020-10-15
AU2018355588A1 (en) 2020-06-11
US20200010551A1 (en) 2020-01-09
KR102162129B1 (ko) 2020-10-06
US20220332830A1 (en) 2022-10-20
IL280648B1 (en) 2024-06-01
IL274152B (en) 2021-02-28
JP2021153585A (ja) 2021-10-07
JP7307443B2 (ja) 2023-07-12
AU2018355588C1 (en) 2023-04-27
EP3625263A4 (en) 2021-05-05
JP2022116325A (ja) 2022-08-09
CN111511765A (zh) 2020-08-07
JP2024133590A (ja) 2024-10-02
SG11202003652QA (en) 2020-05-28
WO2019084553A1 (en) 2019-05-02
US10344091B2 (en) 2019-07-09
US10450374B2 (en) 2019-10-22
KR20200064150A (ko) 2020-06-05
AU2020294364B2 (en) 2023-09-21
JP7523084B2 (ja) 2024-07-26
CN115261392A (zh) 2022-11-01
AU2020294364A1 (en) 2021-02-18
AU2023285898A1 (en) 2024-01-18
CN115261392B (zh) 2025-05-13
IL280648A (en) 2021-03-25
CN111511765B (zh) 2022-05-27

Similar Documents

Publication Publication Date Title
DK3625263T3 (da) Anti-galectin- 9-antistoffer og anvendelser deraf
DK3383916T3 (da) Anti-CD73-antistoffer og anvendelser deraf
IL272183A (en) Anti-cd8 antibodies and uses thereof
IL272330A (en) Anti-cd47 antibodies and uses thereof
IL262095A (en) Anti-pacap antibodies and uses thereof
EP3759143A4 (en) ANTI-TIGIT ANTIBODIES AND THEIR USES
DK3468990T3 (da) Anti-C5-antistoffer og anvendelser deraf
EP3740224A4 (en) ANTI-LILRB ANTIBODIES AND THEIR USES
DK3458479T3 (da) Anti-b7-h3-antistoffer og antistof-lægemiddelkonjugater
DK3443009T3 (da) Anti-tim-3-antistoffer og sammensætninger
DK3532499T3 (da) ANTI-IL-33-antistoffer og anvendelser deraf
DK3350220T3 (da) Anti-pro/latente-myostatin-antistoffer og anvendelser deraf
DK3504242T3 (da) Anti-ox40-antistoffer og anvendelse deraf
DK3610005T3 (da) Peptidligase og anvendelse deraf
DK3402821T5 (da) Psma-bindende antistof og anvendelser deraf
DK3283106T3 (da) Terapeutiske antistoffer og anvendelser deraf
DK3333191T3 (da) Anti-C10ORF54-antistoffer og anvendelser deraf
DK3126388T3 (da) Anti-EGFRvIII-antistoffer og anvendelser deraf
DK3365368T3 (da) Tgfbeta1-bindende immunoglobuliner og anvendelse deraf
DK3307274T3 (da) Anti-cd123-antistoffer og konjugater deraf
DK3463435T3 (da) Alpha-synuklein-antistoffer og anvendelser deraf
DK3274370T3 (da) Anti-ceacam6-antistoffer og anvendelser deraf
EP3735427A4 (en) ANTI-MCT1 ANTIBODIES AND ASSOCIATED USES
IL271398A (en) Anti-l1-cam antibodies and uses thereof
EP3733702A4 (en) ANTI-LAG-3 ANTIBODIES AND ASSOCIATED USES